Dallas Diabetes Endocrine Center

Dallas, Texas 75230-2548

0 studies enrolling now · 37 studies all time

What they study most

Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Type 2, Diabetes Type 2, Diabetes, Type 1, Diabetes, Type 2, Diabetes, Type I, Diabetic Peripheral Neuropathic Pain, Diabetic Polyneuropathy, Non-Alcoholic Fatty Liver Disease, Renal Insufficiency, Type 1 Diabetes, Type 1 Diabetes Mellitus

Studies at this site

• A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk — Completed
• Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2) — Completed
• A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone — Completed
• A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes — Completed
• A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes — Completed
• A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus — Completed
• A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy — Completed
• Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency — Completed
• Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study) — Completed
• A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus — Completed
• A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes — Completed
• An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus — Completed
• A Study of LY900014 in Participants With Type 1 Diabetes — Completed
• A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease — Completed
• A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes — Completed
• Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes — Completed
• A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus — Stopped early
• A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) — Stopped early
• A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes — Stopped early
• A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy — Completed
• A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus — Completed
• A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus — Completed
• Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes — Completed
• Add-on to Thiazolidinedione (TZD) Failures — Completed
• BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes — Completed
• Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes — Completed
• Diabetic Peripheral Neuropathic Pain (DPNP) — Completed
• Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin — Completed
• A 2-Month Safety Follow-Up Trial — Completed
• Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler — Stopped early
• Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes — Completed
• An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial — Completed
• Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks — Stopped early
• Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up — Completed
• Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes — Completed
• Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166 — Stopped early
• Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione — Completed